ASX:TTB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Total Brain Limited, together with its subsidiaries, develops and sells brain health products in the United States. More Details


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has Total Brain's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TTB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

11.8%

TTB

1.0%

AU Healthcare

0.5%

AU Market


1 Year Return

-22.4%

TTB

5.3%

AU Healthcare

-5.6%

AU Market

Return vs Industry: TTB underperformed the Australian Healthcare industry which returned 5.3% over the past year.

Return vs Market: TTB underperformed the Australian Market which returned -5.6% over the past year.


Shareholder returns

TTBIndustryMarket
7 Day11.8%1.0%0.5%
30 Day-2.6%5.3%5.0%
90 Day18.8%6.4%2.9%
1 Year-22.4%-22.4%7.4%5.3%-2.3%-5.6%
3 Year-38.5%-38.7%23.4%13.5%12.4%-1.2%
5 Year-82.7%-82.7%31.6%13.6%41.5%12.9%

Price Volatility Vs. Market

How volatile is Total Brain's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Total Brain undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TTB (A$0.38) is trading below our estimate of fair value (A$1.12)

Significantly Below Fair Value: TTB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TTB is unprofitable, so we can't compare its PE Ratio to the AU Healthcare industry average.

PE vs Market: TTB is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TTB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TTB's PB Ratio (1.6x) is in line with the AU Healthcare industry average.


Next Steps

Future Growth

How is Total Brain forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

115.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TTB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: TTB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TTB's is expected to become profitable in the next 3 years.

Revenue vs Market: TTB's revenue (69.1% per year) is forecast to grow faster than the Australian market (4.6% per year).

High Growth Revenue: TTB's revenue (69.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TTB's Return on Equity is forecast to be low in 3 years time (8.7%).


Next Steps

Past Performance

How has Total Brain performed over the past 5 years?

-15.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TTB is currently unprofitable.

Growing Profit Margin: TTB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TTB is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.

Accelerating Growth: Unable to compare TTB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TTB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-6.1%).


Return on Equity

High ROE: TTB has a negative Return on Equity (-28.98%), as it is currently unprofitable.


Next Steps

Financial Health

How is Total Brain's financial position?


Financial Position Analysis

Short Term Liabilities: TTB's short term assets (A$14.1M) exceed its short term liabilities (A$3.0M).

Long Term Liabilities: TTB's short term assets (A$14.1M) exceed its long term liabilities (A$67.4K).


Debt to Equity History and Analysis

Debt Level: TTB's debt to equity ratio (4.2%) is considered satisfactory.

Reducing Debt: TTB's debt to equity ratio has reduced from 46.1% to 4.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TTB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TTB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Total Brain current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TTB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TTB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TTB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TTB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TTB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Louis Gagnon

3.42yrs

Tenure

AU$458,873

Compensation

Mr. Louis Gagnon has been Chief Executive Officer of Total Brain Limited (formerly known as Brain Resource Limited) since May 22, 2017 and has been its Managing Director since December 22, 2017. Mr. Gagnon ...


CEO Compensation Analysis

Compensation vs Market: Louis's total compensation ($USD325.17K) is about average for companies of similar size in the Australian market ($USD277.02K).

Compensation vs Earnings: Louis's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Evian Gordon
Founder & Executive Chairmanno dataAU$476.47k1.2%
A$ 494.7k
Louis Gagnon
MD, CEO & Director3.42yrsAU$458.87k0.38%
A$ 158.0k
Emil Vasilev
Vice President of Finance3.42yrsAU$256.09k0.065%
A$ 26.7k
Matthew Mund
Chief Operating Officer3.17yrsAU$377.47k0.91%
A$ 375.7k
Marcel Legrand
Head of Revenue & Corporate Development3.17yrsno datano data
Matt Resteghini
Chief Marketing Officer2.67yrsno datano data
Simon Poidevin
President of Australia & New Zealand0.58yrno datano data
Melissa Frieswick
Chief Revenue Officer0.17yrno datano data
Phillip Hains
Joint Company Secretary2.25yrsno datano data
Nathan Jong
Joint Company Secretary0.92yrno datano data

2.7yrs

Average Tenure

Experienced Management: TTB's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Evian Gordon
Founder & Executive Chairmanno dataAU$476.47k1.2%
A$ 494.7k
Louis Gagnon
MD, CEO & Director3.42yrsAU$458.87k0.38%
A$ 158.0k
Matthew Morgan
Independent Non-Executive Director4.58yrsAU$62.41k0.41%
A$ 169.0k
David Daglio
Non-Executive Director0.75yrAU$20.32k6.42%
A$ 2.6m
David Torrible
Non-Executive Director1.33yrsAU$153.33k5.59%
A$ 2.3m

2.1yrs

Average Tenure

Experienced Board: TTB's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.3%.


Top Shareholders

Company Information

Total Brain Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Total Brain Limited
  • Ticker: TTB
  • Exchange: ASX
  • Founded: 2000
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$41.155m
  • Shares outstanding: 108.30m
  • Website: https://www.totalbrain.com

Number of Employees


Location

  • Total Brain Limited
  • 15 Belvoir Street
  • Surry Hills
  • New South Wales
  • 2010
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TTBL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDAug 2001
TTBASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 2001
BRRZ.YOTCPK (Pink Sheets LLC)SPONSORED ADSUSUSDApr 2011

Biography

Total Brain Limited, together with its subsidiaries, develops and sells brain health products in the United States. It offers Total Brain, a neuroscience-based mental health and brain performance app. Tota ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 10:34
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.